This article has Open Peer Review reports available.
Co-inhibition of epidermal growth factor receptor and insulin-like growth factor receptor 1 enhances radiosensitivity in human breast cancer cells
© Li et al.; licensee BioMed Central Ltd. 2013
Received: 9 October 2012
Accepted: 12 June 2013
Published: 19 June 2013
Over-expression of epidermal growth factor receptor (EGFR) or insulin-like growth factor-1 receptor (IGF-1R) have been shown to closely correlate with radioresistance of breast cancer cells. This study aimed to investigate the impact of co-inhibition of EGFR and IGF-1R on the radiosensitivity of two breast cancer cells with different profiles of EGFR and IGF-1R expression.
The MCF-7 (EGFR +/−, IGF-1R +++) and MDA-MB-468 (EGFR +++, IGF-1R +++) breast cancer cell lines were used. Radiosensitizing effects were determined by colony formation assay. Apoptosis and cell cycle distribution were measured by flow cytometry. Phospho-Akt and phospho-Erk1/2 were quantified by western blot. In vivo studies were conducted using MDA-MB-468 cells xenografted in nu/nu mice.
In MDA-MB-468 cells, the inhibition of IGF-1R upregulated the p-EGFR expression. Either EGFR (AG1478) or IGF-1R inhibitor (AG1024) radiosensitized MDA-MB-468 cells. In MCF-7 cells, radiosensitivity was enhanced by AG1024, but not by AG1478. Synergistical radiosensitizing effect was observed by co-inhibition of EGFR and IGF-1R only in MDA-MB-468 cells with a DMF10% of 1.90. The co-inhibition plus irradiation significantly induced more apoptosis and arrested the cells at G0/G1 phase in MDA-MB-468 cells. Only co-inhibition of EGFR and IGF-1R synergistically diminished the expression of p-Akt and p-Erk1/2 in MDA-MB-468 cells. In vivo studies further verified the radiosensitizing effects by co-inhibition of both pathways in a MDA-MB-468 xenograft model.
Our data suggested that co-inhibition of EGFR and IGF-1R synergistically radiosensitized breast cancer cells with both EGFR and IGF-1R high expression. The approach may have an important therapeutic implication in the treatment of breast cancer patients with high expression of EGFR and IGF-1R.
Currently, breast cancer is the most common malignancy among women worldwide. Radiotherapy is considered mandatory for most patients undergoing breast-conserving surgery and appropriate for women at high risk of recurrence after mastectomy, but the locoregional control of breast cancer patients still is disappointed, especially in some subtypes like basal-like breast cancer . The patients with basal-like breast cancer are associated with a high risk of local-regional failure compared to other subtypes [1, 2]. One of the features of the patients is that they have abnormal signaling transduction pathways like epidermal growth factor receptor (EGFR) and insulin like growth factor 1 receptor (IGF-1R) [3, 4]. These receptor tyrosine kinases have been implicated in radioresistance of breast cancer in preclinical and clinical studies [3, 5, 6], therefore, the combination of targeted therapy with radiotherapy has been investigated to improve local control rates .
Clinical studies of EGFR inhibitors might aid in the clinical introduction of anti-IGF-1R targeting strategies. Interactions between IGF-IR and EGFR signaling pathways have been previously described . The interaction exists on multiple levels, either through a direct association between the two receptors, or indirectly via common interaction partners such as downstream effectors . Sensitivity to EGFR inhibition has been linked to acquired mutations in the ATP binding site of the EGFR kinase domain and to increased IGF signaling, Co-inhibition of EGFR and IGF-1R has been found to cause synergy in growth inhibition and apoptosis induction in human breast cancer cells . Considering the interplay between the IGF-1 and EGF systems and their role in the modulation of radiosensitivity, targeting multiple signaling pathways may maximize the response to irradiation.
Synergistic radiosensitization has been achieved by co-inhibition of multi-targets . However, there are no reports about the impacts of co-inhibition of EGFR and IGR-1R on radiosensitivity of breast cancer cells. In this study, we aimed to investigate whether co-inhibition of EGFR and IGF-1R enhances the radiosensitivity of breast cancer cells with different expression of the two receptors, and also to assess the potential molecular mechanisms.
Cell lines and culture
The human breast cancer cell lines MDA-MB-468 (basal-like cell line with high expression of EGFR and IGF-1R) and MCF-7 (luminal-like cell line with high expression of IGF-1R, but low expression of EGFR) were used in this study , and purchased from the American Type Culture Collection (ATCC, Manassas, VA). The cells were cultured in Eagle’s MEM supplemented with 10% fetal bovine serum and 1% penicillin-streptomycin (GIBIC).
All antibodies were purchased from the Cell Signaling Technology, Inc (Danvers MA). The selective EGFR tyrosine kinase inhibitor (AG1478) and the IGF-1R tyrosine kinase inhibitor (AG1024) were purchased from Calbiochem (La Jolla CA). The inhibitors were dissolved in DMSO to prepare a 10 mM stock solution.
Cells in a monolayer were irradiated at room temperature using 6MV X-rays from linear accelerators (Siemens, Germany) with dose rate of 3 Gy/min. A 1.5-cm bolus was used as a compensator
Cell viability assay
Cells were incubated in the presence of serial increasing concentrations of AG1478 or AG1024 for 48 h. Then, 20 μM of MTT solution (5 mg/ml) was added into each well for 4 h. The reaction was stopped by removal of MTT, and 150 μl DMSO was added into each well, and then the plates were read at 570 nm. Percentage of cell viability was determined relative to control. Each experiment was done in six replicate wells for each drug concentration. All experiments were done in triplicate. The IC50 values were calculated with the SPSS software using bliss method.
Colony formation assay
105 Cells were seeded in 60 mm culture dishes, twenty- four hours later cells were treated with 10 μM AG1478 or/and 10 μM AG1024, control group received DMSO in the same concentration for 1 hour. Then cells were irradiated with single dose at 0 to 10 Gy with 6MV x rays. At 48 hours post-irradiation, the cells were detached from dishes with trypsin, and were seeded at various dilutions into 60 mm dishes in normal medium. The cells were cultured for 14 days. Each result was the average of at least three independent experiments. Colonies (>50 cells/colony) were fixed and stained with crystal violet. Survival curves were fitted by the linear-quadratic model using the Graphpad prism soft (version 5.0). Dose-modifying factor at 10% survival cells (DMF10%) were determined by taking the ratio of the radiation doses at the 10% survival level.
Apoptosis and cell cycle assay by flow cytometry
Cells were treated with inhibitors (10 μM) for 1 h and were irradiated with 4Gy. They were harvested and washed with PBS at 48 hours after treatment. They were stained with propidium iodide (PI) and Annexin V (KeyGEN, Inc. Nanjing, China) for 10-20 min, and were detected by flow cytometry (Beckman Coulter, Inc.). For the analyses of cell cycle, the treated cells were fixed in 70% ethanol and stored at −20°C overnight; the cells were labeled with propidium iodide (50 μg/ml) and RNase (100 μg/ml) for 30 min before the analyses by flow cytometry with Multi-cycle system software package.
Western blot analysis
MDA-MB-468 cells were exposed to 10 μM of AG1478 and/or 10 μM of AG1024 for 1 hour, and then incubated with the inhibitors after irradiated at 4Gy. After incubation for 24 hours, the cells were lysed and separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis and transferred to polyvinylidene fluoride membrane, the membrane were incubated overnight with primary antibodies at 4°C with gentle shaking, and then were incubated for 2 h with horseradish peroxidase–labeled secondary antibody. All membranes were detected using the ECL plus chemifluorescent reagent (Amersham Biosciences). The extent of protein expression were quantified by the ImageJ soft from NIH  and normalized by the value of control expression in each group.
In vivo studies
Female athymic nu/nu mice (4 to 6 weeks old) were obtained from laboratory animal center of Shanghai institutes for biological sciences, Chinese Academy of Sciences (Permit Number: SCXK 2007–005). All animal studies were strictly in accordance with a protocol approved by Ethic Committee for Animal Experimentation of Shanghai Jiaotong University. 5 × 106 MDA-MB-468 cells were injected into the flanks of female athymic nu/nu mice. The mice with tumor volume 100 mm3 were randomly divided into five groups (5 mice/group), and treated with variable strategies. AG1478 were intraperitoneally injected with 10 mg/kg three times per week for 2 weeks and AG1024 were intraperitoneally injected with 1.5 mg/kg once per day for 2 weeks. Mice were irradiated 30 min after injection of inhibitors with 8 Gy on the first day. Tumor volume for xenografts was determined by a caliper and was calculated as volume = length × width2/2, where the width is the smallest measurement and the length is the longest measurement .
Each experiments were performed in triplicate. For comparison of the difference between two groups, Student’s t test was used. For comparison of the difference between more than two groups, One-way ANOVA, Bonferroni were employed for statistical analysis using SPSS 11.0 for windows software. p values <0.05 were considered as statistically significant.
The impact of inhibition of EGFR or IGF-1R on the cell viability
Co-inhibition of EGFR and IGF-1R synergistically enhanced the radiosensitizing effect in MDA-MB-468 cells but not in MCF-7 cells
Co-inhibition of EGFR and IGF-1R combined with irradiation induced more apoptosis in MDA-MB-468 cells not in MCF-7 cells
Co-inhibition of EGFR and IGF-1R combined with irradiation significantly induced G0/G1 arrest in MDA-MB-468 cells
Enhancement of the radiosensitizing effect of MDA-MB-468 cells through synergistical downregulation of Akt and Erk1/2
Co-inhibition of EGFR and IGF-1R combined with irradiation significantly inhibits MDA-MB-468 xenograft growth
EGFR and IGF-1R are commonly overexpressed in a significant number of cancers, included breast cancer [13, 14], and its overexpression have been implicated to influence the response to irradiation in breast cancer cells . There were about 65% with the overexpression of EGFR and 22.5% with the overexpression of IGF-1R in basal-like breast cancer patients [4, 6]. The abnormal expression of those receptors have been observed to be associated with poor prognosis and unfavorable response to radiotherapy . Since there were a cross-talk between EGFR and IGF-1R pathways and the cross-talk may be one of reasons for the resistance of cancer cells to drug and radiotherapy [16, 17], co-inhibition of both pathways have been investigated and found out that it could synergistically inhibit tumor proliferation and growth [7, 15]. Therefore, we hypothesized that co-inhibition of EGFR and IGF-1R would further impact the response of breast cancer cells to irradiation.
In our studies, the different response to irradiation after co-inhibition of EGFR and IGF-1R in MDA-MB-468 and MCF-7 cells adds to the evidence that both signaling pathways may be involved in the treatment response. Firstly, the radiosensitizing effect by either EGFR or IGF-1R inhibitor depended on the expression level of EGFR and IGF-1R in both cells. Secondly, inhibition of IGF-1R resulted in a slight upregulation of p-EGFR in MDA-MB-468 cells, which corroborates the study by other reports [15, 18]. Furthermore, both cell lines had a different sensitivity to AG1024 although both cell lines had similar expression level of IGF-1R (Figure 1b). Those findings supported that there were the interaction between EGFR and IGF-1R. Co-inhibition of EGFR and IGF-1R plus irradiation resulted in significantly increased apoptosis and mitotic death relative to any single inhibitor plus irradiation in MDA-MB-468 cells. In addition, in vivo studies further verify the radiosensitizing effects by co-inhibition of EGFR and IGF-1R in MDA-MB-468 xenografts. These results added the evidence that both EGFR and IGF-1R may be involved in the regulation of radiosensitivity, the response to radiotherapy in breast cancer like basal-like subtype may be improved by co-targeting EGFR and IGF-IR.
The possible mechanism for synergistical radiosensitizing effect by co-targeting EGFR and IGF-IR may be associated with their collective downstream pathways -- PI3K/Akt and Ras/Raf/MAPK, both pathways involved in the regulation of radiosensitivity through the downstream proteins Akt and Erk1/2 [19, 20]. It has been reported that inhibition of PI3K/Akt signaling pathway led to radiosensitize the tumor cell by affecting repair of DNA double-strand breaks via DNA-PKcs, and this pathway inactivates Bad and caspase-9 and activates p21, p27 and Mre11, which are associated with cellular radiosensitivity [21, 22]. Activated Erk1/2 has also been observed to confer radioresistance in breast cancer cells . Inhibition of both Akt and Erk1/2 may achieve synergistic radiosensitization in some subtypes of cancer cells. In present study, we found that co-inhibition of EGFR and IGF-1R could completely abolished the p-Akt and p-Erk1/2 and resulted in a synergistic radiosensitizing effect in MDA-MB-468 cells. These results suggested that co-targeting EGFR and IGF-1R radiosensitized the MDA-MB-468 cells through both PI3K/Akt and MAPK signaling pathways.
In addition to the potential of growth factor inhibitors to reverse pro-survival signal, they may also sensitize cells to irradiation by altering cell cycle control. The growth factor inhibitors have been shown to induce G0/G1 arrest, and this alteration redistributes cells from relatively radioresistant S phase to more sensitive phase like late G1 or G2/M . On the other hand, although tumor cells arrest at some checkpoints in order to repair radiation-induced damage, it require growth factors to proceed effectively , therefore, inhibition of growth factor receptor make the process unable to facilitate repair, contributing to cell death. Our data show that co-targeting EGFR and IGF-1R plus irradiation significantly reduced S phase and arrest cells at G0/G1 phase in MDA-MB-468 cells, profound tumor cell kill was observed, therefore, the cells were sensitized to irradiation.
In summary, both in vitro and in vivo studies support that synergistic radiosensitizing effect by co-inhibition of both pathways mainly through the synergistic downregulation of p-Akt and p-Erk1/2. Our results suggest that the strategy of block more than one pathway holds promise to enhance the radiosensitivity of some subtypes breast cancer, but it is critical to evaluate the profile of expression of EGFR and IGF-1R in breast cancer patients before the strategy is applied into the clinical setting.
This article is funded by the research grant (YG2012ZD02, 12JC1407400) from Shanghai Jiaotong University and the Science & Technology Commission of Shanghai, China and the grant (81272506, 61227017) from National Natural Science Foundation of China.
- Voduc KD, Cheang MC, Tyldesley S, Gelmon K, Nielsen TO, Kennecke H: Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol. 2010, 28: 1684-1691. 10.1200/JCO.2009.24.9284.View ArticlePubMedGoogle Scholar
- Wong FY, Chin FK, Lee KA, Soong YL, Chua ET: Hormone receptors and HER-2 status as surrogates for breast cancer molecular subtypes prognosticate for disease control in node negative Asian patients treated with breast conservation therapy. Ann Acad Med Singapore. 2011, 40: 90-97.PubMedGoogle Scholar
- Livasy CA, Karaca G, Nanda R, Tretiakova MS, Olopade OI, Moore DT, Perou CM: Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol. 2006, 19: 264-271. 10.1038/modpathol.3800528.View ArticlePubMedGoogle Scholar
- Yerushalmi R, Gelmon KA, Leung S, Gao D, Cheang M, Pollak M, Turashvili G, Gilks BC, Kennecke H: Insulin-like growth factor receptor (IGF-1R) in breast cancer subtypes. Breast Cancer Res Treat. 2012, 132: 131-142. 10.1007/s10549-011-1529-8.View ArticlePubMedGoogle Scholar
- Gee JM, Nicholson RI: Expanding the therapeutic repertoire of epidermal growth factor receptor blockade: radiosensitization. Breast Cancer Res. 2003, 5: 126-129. 10.1186/bcr584.View ArticlePubMedPubMed CentralGoogle Scholar
- Taunk NK, Goyal S, Moran MS, Yang Q, Parikh R, Haffty BG: Prognostic significance of IGF-1R expression in patients treated with breast-conserving surgery and radiation therapy. Radiother Oncol. 2010, 96: 204-208. 10.1016/j.radonc.2010.03.009.View ArticlePubMedGoogle Scholar
- van der Veeken J, Oliveira S, Schiffelers RM: Storm G, van Bergen En Henegouwen PM, Roovers RC: Crosstalk between epidermal growth factor receptor- and insulin-like growth factor-1 receptor signaling: implications for cancer therapy. Curr Cancer Drug Targets. 2009, 9: 748-760. 10.2174/156800909789271495.View ArticlePubMedGoogle Scholar
- Camirand A, Zakikhani M, Young F, Pollak M: Inhibition of insulin-like growth factor-1 receptor signaling enhances growth-inhibitory and proapoptotic effects of gefitinib (Iressa) in human breast cancer cells. Breast Cancer Res. 2005, 7: R570-R579.View ArticlePubMedPubMed CentralGoogle Scholar
- Sambade MJ, Kimple RJ, Camp JT, Peters E, Livasy CA, Sartor CI, Shields JM: Lapatinib in combination with radiation diminishes tumor regrowth in HER2+ and basal-like/EGFR + breast tumor xenografts. Int J Radiat Oncol Biol Phys. 2010, 77: 575-581. 10.1016/j.ijrobp.2009.12.063.View ArticlePubMedPubMed CentralGoogle Scholar
- Voss MJ, Möller MF, Powe DG, Niggemann B, Zänker KS, Entschladen F: Luminal and basal-like breast cancer cells show increased migration induced by hypoxia, mediated by an autocrinemechanism. BMC Cancer. 2011, 11: 158-10.1186/1471-2407-11-158.View ArticlePubMedPubMed CentralGoogle Scholar
- Carracedo A, Ma L, Teruya-Feldstein J, Rojo F, Salmena L, Alimonti A, Egia A, Sasaki AT, Thomas G, Kozma SC, Papa A, Nardella C, Cantley LC, Baselga J, Pandolfi PP: Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest. 2008, 118: 3065-3074.PubMedPubMed CentralGoogle Scholar
- Shi Y, Felley-Bosco E, Marti TM, Orlowski K, Pruschy M, Stahel RA: Starvation-induced activation of ATM/Chk2/p53 signaling sensitizes cancer cells to cisplatinduced activation of ATM/Chk2/p53 signaling sensitizes cancer cells to cisplatin. BMC Cancer. 2012, 12: 571-10.1186/1471-2407-12-571.View ArticlePubMedPubMed CentralGoogle Scholar
- Shimizu C, Hasegawa T, Tani Y, Takahashi F, Takeuchi M, Watanabe T, Ando M, Katsumata N, Fujiwara Y: Expression of insulin-like growth factor 1 receptor in primary breast cancer: immunohistochemical analysis. Hum Pathol. 2004, 35: 1537-1542. 10.1016/j.humpath.2004.09.005.View ArticlePubMedGoogle Scholar
- Jameel JK, Rao VS, Cawkwell L, Drew PJ: Radioresistance in carcinoma of the breast. Breast. 2004, 13: 452-460. 10.1016/j.breast.2004.08.004.View ArticlePubMedGoogle Scholar
- Buck E, Eyzaguirre A, Rosenfeld-Franklin M, Thomson S, Mulvihill M, Barr S, Brown E, O’Connor M, Yao Y, Pachter J, Miglarese M, Epstein D, Iwata KK, Haley JD, Gibson NW, Ji QS: Feedback mechanisms promote cooperativity for small molecule inhibitors of epidermal and insulin-like growth factor receptors. Cancer Res. 2008, 68: 8322-8332. 10.1158/0008-5472.CAN-07-6720.View ArticlePubMedGoogle Scholar
- Luwor RB, Lu Y, Li X, Liang K, Fan Z: Constitutively active Harvey Ras confers resistance to epidermal growth factor receptor-targeted therapy with cetuximab and gefitinib. Cancer Lett. 2011, 306: 85-91. 10.1016/j.canlet.2011.02.035.View ArticlePubMedPubMed CentralGoogle Scholar
- Wei F, Liu Y, Bellail AC, Olson JJ, Sun SY, Lu G, Ding L, Yuan C, Wang G, Hao C: K-Ras mutation-mediated IGF-1-induced feedback ERK activation contributes to the rapalog resistance. Cancer Lett. 2012, 322: 58-69. 10.1016/j.canlet.2012.02.005.View ArticlePubMedPubMed CentralGoogle Scholar
- Nicholson RI, Hutcheson IR, Knowlden JM, Jones HE, Harper ME, Jordan N, Hiscox SE, Barrow D, Gee JM: Nonendocrine pathways and endocrine resistance: observations with antiestrogens and signal transduction inhibitors in combination. Clin Cancer Res. 2004, 10: 346S-354S. 10.1158/1078-0432.CCR-031206.View ArticlePubMedGoogle Scholar
- Sambade MJ, Camp JT, Kimple RJ, Sartor CI, Shields JM: Mechanism of lapatinib-mediated radiosensitization of breast cancer cells is primarily by inhibition of the Raf > MEK > ERK mitogen-activated protein kinase cascade and radiosensitization of lapatinib-resistant cells restored by direct inhibition of MEK. Radiother Oncol. 2009, 93: 639-644. 10.1016/j.radonc.2009.09.006.View ArticlePubMedPubMed CentralGoogle Scholar
- Albert JM, Kim KW, Cao C: LuB: Targeting the Akt/mammalian target of rapamycin pathway for radiosensitization of breast cancer. Mol Cancer Ther. 2006, 5: 1183-1189. 10.1158/1535-7163.MCT-05-0400.View ArticlePubMedGoogle Scholar
- Deng R, Tang J, Ma JG, Chen SP, Xia LP, Zhou WJ, Li DD, Feng GK, Zeng YX, Zhu XF: PKB/Akt promotes DSB repair in cancer cells through upregulating Mre11 expression following ionizing radiation. Oncogene. 2010, 30: 944-955.View ArticlePubMedGoogle Scholar
- Liang J, Slingerland JM, Slingerland JM: Multiple roles of the PI3K/PKB (Akt) pathway in cell cycle progression. Cell Cycle. 2003, 2: 339-345.View ArticlePubMedGoogle Scholar
- Zhang Y, Wang J, Liu F, You Z, Yang R, Zhao Y: EGFR inhibitor C225 increases the radiosensitivity of human lung squamous cancer cells. Cancer Cell Int. 2010, 10: 39-10.1186/1475-2867-10-39.View ArticlePubMedPubMed CentralGoogle Scholar
- Dent P, Reardon DB, Park JS, Bowers G, Logsdon C, Valerie K, Schmidt-Ullrich R: Radiation-induced release of transforming growth factor alpha activates the epidermal growth factor receptor and mitogen-activated protein kinase pathway in carcinoma cells, leading to increased proliferation and protection from radiation-induced cell death. Mol Biol Cell. 1999, 10: 2493-2506.View ArticlePubMedPubMed CentralGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://0-www.biomedcentral.com.brum.beds.ac.uk/1471-2407/13/297/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.